Suppression of non-small cell lung tumor development by the let-7 microRNA family

By Madhu S. Kumar, S. Erkeland, Ryan E. Pester, Cindy Y. Chen, Margaret S. Ebert, Phillip A. Sharp, T. Jacks. Proceedings of the National Academy of Sciences of the United States of America, 2008

932 citations recorded by the source corpus.

View Paper: https://www.semanticscholar.org/paper/e306bb8517216df00321e4d4f2017d48bfde8077

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

Citations in the corpus

MicroRNA Functions in Stress Responses (2010, unknown): “…let-7 and IL-6 as an example (Figure 3B): a reduction of let-7 level, which is commonly observed in tumors (Esquela-Kerscher and Slack, 2006; Kumar et al., 2008; Lu et al., 2005), lowers the threshold of extracellular IL-6 that is required to trigger cancer cell transformation (Iliopoulos…”
A SNP in a let-7 microRNA complementary site in the KRAS 3′UTR Increases Non-Small Cell Lung Cancer Risk (2008, background): “12, 13); their lower levels are biomarkers of a poor outcome (14, 15); they regulate multiple important lung cancer oncogenes, including RAS (12, 16); and they inhibit growth of lung cancer cell lines in vitro (12, 14) and in vivo (17, 18).”
The Lin28/let-7 axis regulates glucose metabolism (2011, background): “The let-7 miRNA family members act as tumor suppressors by negatively regulating the translation of oncogenes and cell cycle regulators (Johnson et al., 2005; Lee and Dutta, 2007;Mayr et al., 2007; Kumar et al., 2008).”
Silencing of microRNA families by seed-targeting tiny LNAs (2011, background): “Given the emerging roles of miRNA seed families in disease, such as the let-7 family in lung cance”
The microcosmos of cancer (2012, background): “If this were possible it would undoubtedly impact many diseases including cancer by allowing the targeting of oncogenic transcription factors that are difficult to inhibit through traditional medicinal chemistr”
MicroRNAs and cancer: short RNAs go a long way. (2009, background): “Finally, overexpression of let-7 miRNAs can suppress tumor development in mouse models of breast and lung cancer (Kumar et al., 2008; Yu et al., 2007).”
MicroRNA sponges: progress and possibilities. (2010, methodology): “The most commonly used vectors were plasmids (Kumar et al. 2008; Rybak et al. 2008; Elcheva et al. 2009; Edbauer et al. 2010), but some used retroviruses (Bolisetty et al.”
Serum microRNA signatures identified in a genome-wide serum microRNA expression profiling predict survival of non-small-cell lung cancer. (2010, methodology): “two let-7 family members (ie, let-7a and let-7g) with two-fold expression changes between the two groups were included also, because their expressions in tissue specimen were reported to be correlated with lung cancer survival.(18,19) We then performed individual qRT-PCR assay to quantify each of th”
MicroRNAs in development and disease. (2011, background): “It also suppresses growth of tumor xenografts (166, 323) and primary tumors in a K-Ras lung cancer model in vivo, when delivered intranasally via a lentivirus vector (166).”
Therapeutic delivery of miR-26a inhibits cancer cell proliferation and induces tumor-specific apoptosis (2009, unknown): “Supporting this notion, two recent reports demonstrated that viral delivery of let-7 miRNAs suppressed tumor growth in a mouse model of lung adenocarcinoma (Esquela-Kerscher et al., 2008; Kumar et al., 2008).”
miR-19 is a key oncogenic component of mir-17-92. (2009, background): “Multiple miRNAs were subsequently identified to promote or suppress oncogenesis, presumably by modulating gene expression in the oncogenic and tumor suppressor networks (He et al. 2005, 2007a; Johnson et al. 2005; Kumar et al. 2008; Kota et al. 2009).”
An epigenetic switch involving NF-κB, Lin28, let-7 microRNA, and IL6 links inflammation to cell transformation (2009, unknown): “In addition, expression of let-7 RNAs is reduced in non-small-cell lung cancer patients and associated with poor prognosis (Johnson et al., 2005), and let-7 overexpression substantially reduces tumor burden in a K-Ras murine lung cancer model ( Kumar et al., 2008 ).”